recurrence rate up to 6 years [clinicaltrials_resource:709dcceeda142afd2bd3f9d88b398e8f]
The primary endpoint was the time to recurrence(TTR) was measured from the date of treatment to the time when the recurrent tumor was first diagnosed. At spiral CT after treatment, residual viable tumor tissue was considered to be present if enhancing areas were seen within the tumor on either arterial phase or portal venous phase images. Depending on the initial random treatment assignment, RFA-125I or RFA alone was repeated. Magnetic resonance (MR) imaging was performed if there was uncertainty at CT as to whether residual viable tumor tissue was present.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
recurrence rate up to 6 years [clinicaltrials_resource:709dcceeda142afd2bd3f9d88b398e8f]
The primary endpoint was the time to recurrence(TTR) was measured from the date of treatment to the time when the recurrent tumor was first diagnosed. At spiral CT after treatment, residual viable tumor tissue was considered to be present if enhancing areas were seen within the tumor on either arterial phase or portal venous phase images. Depending on the initial random treatment assignment, RFA-125I or RFA alone was repeated. Magnetic resonance (MR) imaging was performed if there was uncertainty at CT as to whether residual viable tumor tissue was present.
Bio2RDF identifier
709dcceeda142afd2bd3f9d88b398e8f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:709dcceeda142afd2bd3f9d88b398e8f
measure [clinicaltrials_vocabulary:measure]
recurrence rate
time frame [clinicaltrials_vocabulary:time-frame]
up to 6 years
description
The primary endpoint was the t ...... able tumor tissue was present.
identifier
clinicaltrials_resource:709dcceeda142afd2bd3f9d88b398e8f
title
recurrence rate up to 6 years
@en
type
label
recurrence rate up to 6 years [clinicaltrials_resource:709dcceeda142afd2bd3f9d88b398e8f]
@en